Leadership

We are a mission-driven and multidisciplinary team of physicists, molecular biologists, geneticists, epidemiologists, computer scientists, chemists, clinicians, drug developers, and entrepreneurs focused on the development and application of AI to patient data to radically transform the discovery and development of new drugs, and ultimately change the way we treat and eventually cure diseases.

Colin Hill

Chief Executive Officer and Co-Founder

Bruce Church, PhD

Chief Mathematics Officer and EVP, Research and Early Development

Joseph F. Donahue

Chief Business Officer

Alan Kilyk

Chief Financial Officer

Jeanne Latourelle, D.Sc.

Senior Vice President Precision Medicine

Jerome Windsor, PharmD

Senior Vice President Business Development & Strategic Alliances

Board of Directors

John Maraganore, PhD

Chair of Aitia Board of Directors, Venture Partner at ARCH Venture Partners, Venture Advisor at Atlas Ventures, Executive Partner at RTW Investments. Former founding CEO and Director of Alnylam.

Colin Hill

Chief Executive Officer and Co-Founder

Jan Berger, MD, MJ

President & Chief Executive Officer, Health Intelligence Partners, Vice Chair of Aitia Board of Directors

Craig Cimini

Vice President of Strategy and Business Development & Cigna Ventures, Cigna

Rob Coppedge

President and Chief Executive Officer, Echo Health Ventures

Timothy Thompson

Independent Director & Former Chairman and Chief Executive Officer, Aptus Health

Adrian Weller, PhD

Senior Research Fellow, University of Cambridge Programme Director, Artificial Intelligence, The Alan Turing Institute

Board Observers

Joel Krikston

Managing Director Venture Investments/Head of Strategic Innovation Alliances, Merck Global Health Innovation Fund

David W. Miller, PhD

Operating Partner, GHO Capital

Samantha Palmer, PhD

Managing Director, Amgen Ventures

Advisors

Tom Daniel

Venture Partner at ARCH, former President of R&D at Celgene

Jean-Michel Gries

President of Hengenix Biotech and Head of Research for Henlius Biotech

Ole Isacson, PhD

Professor Neurology and Neuroscience Harvard Medical School, Massachusetts General Hospital, McLean Hospital, HSCI

Jonathan Keats

Lead Aitia Advisor for Multiple Myeloma, Lead MM Researcher at TGen / City of Hope

William Klitgaard

Former President LabCorp’s Enlighten Health

Peter Neupert

Lead Director at Adaptive and LabCorp, former Corporate Vice President at Microsoft and Founder and Chief Executive Officer of drugstore.com

Lee Newcomer

Board member of Myriad Genetics and CellWorks
Former Senior Vice President, Oncology and Genetics, and Chief Medical Officer at UnitedHealth Group

Ravi B. Parikh, MD, MPP, FACP

Aitia Chief Oncology Advisor
Oncologist and Faculty Member at University of Pennsylvania & Board of Directors at Coalition to Transform Advanced Care

Phil Rowlands, PhD

Independent Consultant, Oncology Drug Development
Former head of Oncology R&D at Takeda
Former VP, Asset Team Leader, Oncology Business Unit at Pfizer

Our Investors

{"infinite":"true","pause_on_hover":"false","adaptive_height":"false","items":"5","auto_play":"true","speed":"1000","rtl_mode":"false","dots":"false","nav":"false","slides_to_scroll":"1","slides_to_scroll_mobile":"1","auto_play_speed":"1000","draggable":"true","swipe":"true","lazy":"false","carousel_mode":"standard","center_mode":"false","center_mode_padding":"60px","vertical":"false","nav_type":"nav_arrow","items_desktop":"4","items_desktop_small":"3","items_tablet":"2","items_mobile":"1","nav_arrow_type_horizon":"angle_arrow_horizon"}

Colin Hill, MS

CEO and Co-Founder

Colin Hill is a leading voice in AI and precision medicine and brings impressive leadership experience in developing and commercializing AI solutions and discoveries in biopharmaceutical drug discovery and development and in managed care industries. Colin currently serves on the board of Centrexion Therapeutics, a biotech company focused on developing and commercializing non-opioid, non-addictive chronic pain drugs.

Colin previously served on the boards of Biotelemetry Inc. (NASDAQ: BEAT), the leading mobile health information company (acquired by Philips in 2021), and PPD Inc. (NASDAQ: PPD), a leading global contract research organization (acquired by Thermo in 2021), and was a founding member of the Board of Directors of AesRx, a biopharmaceutical company dedicated to the development of new treatments for sickle cell disease (acquired by Baxter in 2014).

He was also a founding board member of TMed (Transforming Medicine: The Elizabeth Kauffman Institute), a non-profit foundation (501c3) dedicated to the advancement of personalized medicine. In 2016, he was appointed by Massachusetts Governor Charlie Baker to the Massachusetts Digital Health Council. Colin was the founding chairman of O’Reilly Media’s Strata Rx in 2012, the first healthcare big data conference in the industry. In 2004, Colin was named to MIT Technology Review’s TR100 list of the top 100 innovators in the world under the age of 35.

He is a frequent speaker at national and international scientific and industry conferences and has appeared in numerous publications and television programs, including The Wall Street Journal, CNBC Morning Call & SquawkBox, Nature, Boston Globe, Politico, Forbes, Wired, and The Economist.

He graduated from Virginia Tech with a degree in physics and earned Master’s degrees in physics from both McGill University and Cornell University.

Bruce Church, PhD

Chief Mathematics Officer and EVP, Research and Early Development

Bruce Church is responsible for developing algorithms for REFS and leading projects for the development of new products and technologies. Bruce is a member of the founding team of Aitia.

An expert in statistical physics, machine learning, parallel computing, and causal modeling, Bruce helped develop the original REFS platform. Previously, he spent ten years at Cornell University, developing global optimization methods for computational protein folding, the results of which have been published in several peer-reviewed journals.

Bruce has served as the principal investigator on several major grants, including a $2.5 million award from the Department of Energy. He has served on the Board of Directors for U.S. Rugby and coached the under-23 women’s Northeast rugby team. Bruce received a BS in applied and engineering physics and a PhD in applied physics from Cornell University.

Joseph F. Donahue

Chief Business Officer

Joseph Donahue brings a wealth of expertise to this role, having served in a number of senior leadership and Board positions in life sciences and healthcare organizations throughout his career, including at Accenture, BioReference Laboratories, Genospace, LION Bioscience, Medidata Solutions, Monocl, Spotfire, and Thomson Reuters. Mr. Donahue has excelled at building teams to support Life Sciences organizations with technology and data solutions that lead to novel scientific and business insights and have helped accelerate the discovery, development, and commercialization of new medicines.

Alan Kilyk

CFO

Alan Kilyk joined Aitia as Chief Financial Officer in March 2021. Alan brings more than 30 years of financial and accounting experience with the last 14 being focused in medical device and biotech.

Alan’s most recent position was Chief Financial Officer of Intact Vascular, a private venture capital-backed medical device company, where he worked with the CEO on debt financing and the successful sale of the company to Royal Philips. Prior to that, Alan was Chief Financial Officer at Microchips Biotech, a pre-commercial biotech company, also venture-backed. Alan led the financial integration of Microchips and Keranetics and worked with leadership to develop post-merger corporate strategy, and he was instrumental in the sale of Microchips to Dare Biosciences in 2019. Alan also spent 11 years at Integra LifeSciences in a range of financial leadership roles including Vice President Mergers and Acquisitions Integration and Vice President Corporate Accounting where he led SEC reporting. Alan spent his early career in the telecommunications industry with AT&T and Lucent Technologies.

Alan holds a Bachelor of Arts in Accounting from Stockton University and an MBA from Rutgers School of Business. Alan received a certificate in Coaching and Mentoring from Babson College. Alan is a Certified Public Accountant in the state of New Jersey.

Jeanne Latourelle, D.Sc.

Senior Vice President Precision Medicine

Jeanne Latourelle heads the Precision Medicine team at Aitia. Prior to Aitia in 2015, Jeanne was at the Boston University School of Medicine where she gained over 10 years of experience in NIH-funded academic research, specifically in the field of genetic epidemiology. Her areas of research included statistical genetics of complex disease, with a focus on neurodegenerative disease and pulmonary function. She has co-authored over 40 papers, including high impact publications in Nature, the New England Journal of Medicine, the Journal of the American Medical Association and Lancet Neurology.

Jeanne holds a BS in biomedical engineering from Boston University, a MS in Mechanical Engineering from MIT and a DSc of Epidemiology from Boston University School of Public Health.

Jerome Windsor, PharmD

Senior Vice President Business Development & Strategic Alliances

Jerome Windsor, PharmD, is a biopharma senior leader with broad experience building and growing corporations for payers, pharmaceutical, and digital health companies. He specializes in developing and marketing disruptive technologies at the edge of digital, computer sciences, biology, and pharmacology supporting small and large organizations on both strategy and execution sides. Previously, Jerome was Chief Strategy Officer at Celata Bioinnovations, a venture backed spinout from MIT that operates in machine learning applied to protein regulation pathways and was an advisor to a roster of health-tech ventures. Earlier in his career, Jerome led the global commercial activities of Median Technologies, a digital health imaging company specialized in oncology. Under his tenure, the company pivoted its strategy, built its operations in the US, EU, Japan and China, and increased revenue 20x, providing its radiomics technologies and services to most of the top 10 biopharma companies to better diagnose and treat cancer patients. Prior to this, Jerome was Vice President at i3, a UnitedHealth Group company, a Consultant at Accenture and PwC, and Marketing Product Manager at GSK. Jerome is also a Board Member of the French Tech Boston and a mentor at MassBio, a not-for-profit biotechnology trade association that represents and provides support for the Massachusetts life sciences industry. Jerome earned his PharmD from the University of Normandy and his graduated from ESSSEC Business School in Paris (MBA) and the Wharton Business School (EDP).

John Maraganore, PhD

Aitia Chair of the Board of Directors, Venture Partner at ARCH Venture Partners, Venture Advisor at Atlas Ventures, Executive Partner at RTW Investments. Former founding CEO and Director of Alnylam.

Dr. John Maraganore served as the founding CEO and a Director of Alnylam from 2002 to 2021, where he built and led the company from early platform research on RNA interference through global approval and commercialization of the first four RNAi therapeutic medicines, ONPATTRO^®, GIVLAARI^®, OXLUMO^®, and Leqvio^®. At Alnylam, he also led the company’s value creation strategy, building $25B in market capitalization and forming over 20 major pharmaceutical alliances. He continues to serve on the Alnylam Scientific Advisory Board. Prior to Alnylam, he served in leadership, managerial, and scientific roles at Millennium Pharmaceuticals, Biogen, Zymogenetics, and The Upjohn Comoany. Dr. Maraganore received his M.S. and Ph.D. in biochemistry and molecular biology at the University of Chicago. He is currently a Venture Partner at ARCH Venture Partners, a Venture Advisor at Atlas Ventures, an Executive Partner at RTW Investments, and Senior Advisor for Blackstone Life Sciences. He is also member of the Board of Directors of publicly traded companies (Agios Pharmaceuticals, Beam Therapeutics, Kymera Therapeutics, and Takeda), private companies (Aerium, Hemab, TranSend, and Versanis), and the Biotechnology Industry Organization, where he was Chair from 2017-2019 and is Chair Emeritus. In addition, he serves on the Board of the Termeer Foundation, Chair of the n-Lorem Foundation Advisory Council , and on the Advisory Board of Ariadne Labs. John also serves as a strategic advisor to a number of innovative biotechnology companies, with a focus on mentoring CEOs in their mission to advance science and innovation for patients.

Jan Berger, MD, MJ

President & Chief Executive Officer,Health Intelligence Partners

Vice Chair of Aitia Board of Directors

Jan founded Health Intelligence Partners six years ago as a health care consultancy that blends more than thirty years of business and clinical experience. Health Intelligence Partners has a global focus, working with clients on both short -term and long-term healthcare business strategies and solutions. Jan and Health Intelligence Partners help clients navigate the healthcare environment in order to identify and articulate value opportunities. A great deal of Jan’s focus is on consumer engagement and how it affects the decisions that the consumer makes and the actions that they take.

Prior to founding Health Intelligence Partners, Jan served as Senior Vice President and Chief Clinical Officer for CVS Caremark. During that time, she had Executive Management, P & L, Operations, Innovation and Strategy responsibilities. Before going to CVS Caremark, Jan had 15 years’ experience in healthcare administration within the health plan and academic arenas and lead operations for two population health companies.

As a veteran healthcare executive, Jan’s leadership has delivered results in a variety of settings. Jan offers her experiences and insights through her consulting agency as well as through her participation on healthcare and consumer product boards. She presently sits on healthcare focused boards including AccentCare (Chair; Compliance Committee, Compensation Committee), Aitia, The University of Arizona School of Pharmacy, Harvard Patient Safety Board, Midwest Business Group on Health and Population Health Alliance (Chair: Government Affairs Committee). Jan’s consumer focused boards include Meals to Heal and Whiskerdocs. Jan previously sat on two boards; Care Core National (Committees: Chari: Finance Past Chairperson, Compensation, Search, M&A and Strategic Directions) and Rx-Ante, which were recently sold. She also sits on numerous business and healthcare committees.

As the author of the books “Leveraging Health” and “Thirteen Common Pitfalls in Consumer Engagement” and “Medical Liability for Pediatricians”, the Editor in Chief of American Journal of Pharmacy Benefit and on the editorial boards of a number of healthcare journals, Jan is considered a national health care thought leader. Jan speaks and writes on a broad range of health care issues.

Jan holds both a Doctor of Medicine degree and a Master’s degree in Jurisprudence from Loyola University in Chicago and a Certificate in Healthcare Business Administration from University of South Florida. She also holds a black belt in Six Sigma. Jan is an assistant professor at Northwestern University School of Medicine in Chicago, Illinois.

Craig Cimini

Vice President of Strategy and Business Development & Cigna Ventures, Cigna

Board Member

Craig is responsible for driving business growth via inorganic means. This includes the sourcing and execution of minority investments, joint ventures, and strategic partnerships.

In his current role, Craig leads the investment strategy for Cigna Ventures, Cigna's corporate venture capital fund, which deeply partners with entrepreneurs that are unlocking new growth possibilities in health care. The fund operates to further accelerate Cigna's mission to make healthcare more affordable, predictable, and simple while continuously incubating transformative innovation across three strategic areas: digital health/consumer experience, insights, and analytics, as well as care delivery/enablement.

Craig received a Bachelor of Arts from Gettysburg College and a Master of Health Administration from Cornell University.

Rob Coppedge

Chief Executive Officer, Echo Health Ventures

Board Member

As CEO of Echo Health Ventures, Rob leads the company’s efforts to identify, invest in and grow innovative companies that enable and deliver a transformed experience to health care consumers nationwide. As part of Echo’s unique partnership with its parents, Rob works closely with the senior management teams and board of Cambia Health Solutions and Mosaic Health Solutions to support collaboration with Echo’s portfolio companies, accelerate Cambia and Mosaic’s strategies and more quickly bring health care innovation to national scale. Rob has more than 20 years of experience in health care venture capital and business building. Before founding Echo, Rob served as the President of Cambia Health Solutions’ diversified business unit (Direct Health Solutions). In this role, Rob oversaw Cambia’s wholly-owned operating companies (including cost and quality transparency market leader HealthSparq; ancillary benefits provider LifeMap) as well as its venture and private equity investing activities. Rob joined Cambia in 2010 to launch and build the company’s diversification and corporate venture investment efforts. Under Rob’s leadership, Cambia invested in nearly 20 companies. In 2015, Rob cofounded the Cambia Grove – an innovation hub focused on catalyzing and supporting the Pacific Northwest’s emerging health care economic cluster. At the Cambia Grove, innovators and entrepreneurs work closely with regional stakeholders to find solutions to pressing health care challenges. Before joining Cambia, Rob was the founding partner of Faultline Ventures, where he worked with numerous early stage companies and strategic investors. Previously, he was a Partner at Capitol Health Partners, a Washington, D.C., and New York City-based venture capital firm specializing in early-stage health services and health care information technology. Active in industry and community organizations, Rob serves on the boards of several health care companies and is a founder and former director of the Nashville-based largest network of young health care executives, Leadership Health Care. Rob also serves on the board of directors at Life Science Washington (formerly Washington Biotechnology & Biomedical Association) and the Oregon Museum of Science and Industry (OMSI) and is a member of the American Leadership Forum. Rob is a graduate of Georgetown University with a degree in history and is a Chartered Financial Analyst, charter holder.

Timothy Thompson

Independent Director, Former Chairman and Chief Executive Officer, Aptus Health

Timothy Thompson is the former Chairman and CEO of Aptus Health, a global digital health company whose core platform, Univadis®, delivers medical news, thought leader education, and conference coverage to over four million healthcare professionals around the world. A wholly owned subsidiary of Merck & Co., Aptus Health was acquired by WebMD in 2019. Mr. Thompson currently serves as independent director on the board of Aitia and as an advisor to Echo Health Ventures.

Prior to Aptus Health, Mr. Thompson served as the Chairman and CEO of Intervention insights, a health information services company supporting evidence-based care in molecular oncology. Prior to Intervention Insights, Mr. Thompson served as the President and CEO of Proventys, an innovative healthcare technology company that developed web-based decision support solutions in oncology. Before joining Proventys, Mr. Thompson was a business development executive at Aetna, Inc., serving as Managing Director of mergers & acquisitions and the Head of Strategic Business Development for Aetna Health Information Solutions.

Earlier in his career, Mr. Thompson served as the Chief Operating Officer and Vice President of Business Development for PHT Corporation, a privately held mobile data capture and clinical trial software company. He joined PHT after successfully negotiating the sale of Clinical Data Solutions, Inc. where he had been founder and CEO.

Mr. Thompson received a BA in Zoology and Biochemistry from the University of New Hampshire where he was elected into the Phi Beta Kappa honor society.

Adrian Weller, PhD

Senior Research Fellow, University of Cambridge Programme Director, Artificial Intelligence, The Alan Turing Institute Board Member

Adrian is a Senior Research Fellow in the Machine Learning Group at the University of Cambridge, in the Computational and Biological Learning Lab, and also serves as a Faculty Fellow at The Alan Turing Institute, the United Kingdom’s national institute for data science. Most of his academic research relates to graphical models, but he is also very interested in other areas including finance, anything on intelligence (natural or artificial), deep learning, reinforcement learning, evolution, Bayesian methods, time series analysis, ethics, music and methods for big data.

Prior to his current roles, Adrian served as a Managing Director at Citadel Investment Group where he ran US and European interest rate trading. Earlier, Adrian was in the fixed income proprietary trading group at Salomon Brothers, and previously ran the fixed income options desk at Goldman Sachs.

Adrian completed his PhD in Computer Science from Columbia University, and holds a BA and MA in Mathematics from Trinity College, Cambridge. He is an active angel investor, board member and advisor to many companies and charities apart from Aitia, including Simplex, Cambridge in America, and the Coexist Foundation.

Joel Krikston

Managing Director Venture Investments / Head of Strategic Innovation Alliances, Merck Global Health Innovation Fund Board Observer

Joel Krikston is Managing Director Venture Investments and Head of Strategic Innovation Alliances. Joel is focused on identifying new investment opportunities with a focus on Oncology, Vaccines and Infectious Disease. Mr. Krikston has over 20 years of experience in healthcare innovation. Prior to joining Merck GHI, he was an Investment Principal at Johnson & Johnson Development Corporation. Joel also spent over eight years as an investment banker, covering an array of healthcare clients and included experience at BNP Paribas, JPMorgan and ABN Amro. Joel has an MBA from the Stern School of Business at NYU and completed his Bachelor’s degree in Finance and International Business at Fairfield University.

David W. Miller, PhD

Operating Partner, GHO Capital Board Observer

Dave is an accomplished global pharmaceutical executive and advisor with over 25 years of experience. He is an Operating Partner at GHO Capital, focusing on health care investments. He also operates a specialty advisory practice, advising pharmaceutical executives on pricing, access and health economic and outcomes research strategies. From 2010 to 2017, he was Senior Vice President of Global Market Access at Biogen. He previously worked at Elan, holding roles as Vice President of Pharmacoeconomics and Managing Director. Dr. Miller began his pharmaceutical industry career at GlaxoSmithKline in pharmacoeconomics and assumed increasing responsibilities towards becoming Vice President of Global Health Outcomes. A dual US/UK citizen, he has lived and worked in Europe, Asia and the US. Dr. Miller is the author or co-author of over 70 scientific publications. He is a member of advisory boards at the University of Maryland Baltimore, the University of Washington and Tufts University, and a board member of the Walther Foundation, a charitable organization supporting youth education in the San Francisco Bay Area. He previously served on the Board of Directors of Elan Pharma Ltd and the National Pharmaceutical Council, and was Chair of the Board of Grants for the American Foundation for Pharmaceutical Education. He holds a degree in pharmacy from the University of Iowa and earned his PhD in pharmacy administration at the University of Maryland Baltimore, where he studied health economics and policy.

Samantha Palmer, PhD

Managing Director, Amgen Ventures

Samantha joined Amgen, Inc. in 2015 and is the Managing Director of Amgen Ventures where she directs investments in biopharmaceutical and digital technology companies. She currently serves as a board observer for several portfolio companies including Curate Biosciences and Aetion. She served as an interim Board Observer while Senti Biosciences was finalizing its SPAC merger in 2022. Prior to joining Amgen Ventures, Samantha served as the Chief of Staff and Strategic Planning and Operations Lead for the Office of the CEO and before then was the Business Development Search and Evaluation Lead for the Inflammation Therapeutic Area where she finalized several deals including the asset acquisition of Otezla – approved oral PDE4 small molecule inhibitor for the treatment of psoriasis. Prior to joining Amgen, Samantha was the first employee at Innovimmune Therapeutics where she held Corporate Development and Principal Scientist positions. Samantha earned her PhD in Immunology and Microbial Pathogenesis from Cornell University and an MBA from The Wharton School, University of Pennsylvania.

Michael Bonney

Executive Chairman of Kaleido Biosciences and board member of BMS and Alnylam, former CEO of Cubist

Mike Bonney is Executive Chair of Kaleido Biosciences’ Board of Directors. Previously, Bonney was CEO and Director of Cubist Pharmaceuticals from 2003 until 2014. Under his leadership, Cubist grew from a struggling micro-cap to the world’s leading antibiotic company, and was acquired by Merck early in 2015 for $9.5 billion. Prior to Cubist, Bonney was Vice President of Sales and Marketing at Biogen where he built the company’s commercial infrastructure for the launch of its first product. Before joining Biogen, he spent 11 years at Zeneca Pharmaceuticals in a range of commercial, operating and strategic roles, ending his career there as National Business Director.

Bonney also chairs the boards of Alnylam Pharmaceuticals and Magenta Therapeutics. He is a member of a number of other boards, including Celgene Corporation, Sarepta Therapeutics, and Syros Therapeutics. Bonney spends much of his time identifying and mentoring the next generation of life science leaders.

Bonney was a regional winner and national finalist (2013) in the life science segment of Ernst & Young’s Entrepreneur of the Year and was one of six executives nationwide named as Marketwatch’s CEO of the Year (2011). He received his undergraduate degree in economics from Bates College.

Tom Daniel

Venture Partner at ARCH, former President of R&D at Celgene

Tom Daniel was President, Global Research and Early Development at Celgene Corporation over the last decade, as the company emerged as a leader in defining new mechanisms for drug action, established industry leading collaborative networks, and advanced and commercialized innovative medicines in oncology and inflammatory diseases. He previously served as Chief Scientific Officer and Director of AmbRx, as Vice President of Research at Amgen, and as Senior Vice President of Discovery Research at Immunex Corporation.

Tom is currently Chairman at Vividion Therapeutics, a director at Juno Therapeutics, VIR Biotechnology, Magenta Therapeutics, ImmunsanT and Zafgen. He is a Trustee of Reed College, and serves on the Board of the Alliance for Lupus Research, on the Biomedical Science Advisory Board of Vanderbilt University Medical Center, and is a senior advisor to BlackThorn Therapeutics. A nephrologist and former academic investigator, Tom was previously C.M. Hakim Professor of Medicine and Cell Biology at Vanderbilt.

Dr. Daniel earned his medical degree from the University of Texas, Southwestern, trained in molecular genetics at UTSW, and completed a medical residency at Massachusetts General Hospital.

Jean-Michel Gries

President of Hengenix Biotech, and the Head of Research for Henlius Biotech

Jean-Michel Gries is the President of Hengenix Biotech, and the Head of Research for Henlius Biotech. His responsibility is in shaping the pipeline and research strategy and establishing the ex-China organization. He joined from Kodikaz Therapeutics, a novel non-viral gene therapy company focusing on oncology, where he was the Chief Research and Development Officer. In that capacity, he supported fund raising for the organization, built the research team and developed and implemented the research strategy. Jean-Michel is an accomplished drug development executive. Starting as a director of clinical pharmacology at Aventis (and predecessor companies), he then became the Head of Clinical Pharmacology for Hoffmann-La Roche. He joined Alcon as the Head of R&D for the Pharmaceutical Products Division, in which capacity he led the transformation of the organization to support more innovative mechanism of actions for the treatment of ocular diseases, leading all activities from research to registration. His successes in the drug development space cover both early stage (with over 275 INDs) and late stage (15+ NDAs, 7 ANDAs) and are a testament both of his strong scientific education, and his focus on driving projects forward.

As a business executive, Dr, Gries helped create 9 companies (2 of which are now public) via 26 assets acquisition and led them early on, in a Venture Capital company specialized in the creation and incubation of Biotechnology startups. He has extensive licensing experience from both Roche (member of the licensing committee) and Aventis (Oncology and CNS licensing committee) and Alcon (Board level). Dr. Gries also served on private companies and Not for Profits Boards of Directors.

Dr. Gries has had exposure over a broad set of disease area, Oncology, Inflammation & Pain, CNS, Metabolism, Cardio-Renal, Anti-Infectives (including HIV and HCV), Dermatology, Ophthalmology, Genito-Urinary, Gastro-Enterology. Dr. Gries joined Covance in 2012 as the General Manager for Early Clinical Development, an organization dedicated to help companies achieve their major clinical and investment decision through efficient Proof of Concept or in-patient studies. He built and grew this organization to a very successful business, winning 3 Business Unit of the Year Award. In 2016, Dr Gries joined Parexel International as the General Manager and Strategic Business Unit Leader of its Early Phase Organization, aka the translational medicine arm of Parexel, to lead its transformation. This organization grew over 26% during his tenure.

Dr. Jean-Michel Gries has a PharmD, and a PhD in pharmacokinetics from Rene Descartes University in Paris, a Master in Statistics and a doctoral degree in Analytical Chemistry. He is a Clinical Pharmacology fellow with numerous assignments both in adult and pediatric medicine and a post-doctoral fellowship from UC San Francisco. He also completed a MBA with a Major in Finance and concentration in entrepreneurial Leadership from the Wharton School.

Dr. Gries is the author of more than 30 papers and communications. He has been a fellow of the American College of Clinical Pharmacology since 2001, served on its Finance Committee and on its Board of Regents, and is a reviewer for JCP. He is also a long-time member of ASCPT and was Member of its Board of Director. Jean-Michel is also a long-term member of ASCO.

Ole Isacson, PhD

Professor Neurology & Neuroscience Harvard Medical School, Massachussetts General Hospital, McLean Hospital, HSCI

Dr. Ole Isacson (MD-PhD) is Professor of Neurology (Neuroscience) Massachusetts General Hospital, Harvard Medical School; and the founding and current director of the Neuroregeneration Research Institute at McLean Hospital. Prof. Isacson’s laboratory elucidates biological processes, mechanisms and treatments of neuronal vulnerability in several neurodegenerative diseases, which has resulted in new biotechnologies for restorative treatments using molecular, gene therapy and cell replacement methods; including stem cell derived patient derived neurons. Prof. Isacson is faculty of the Harvard Stem Cell Institute, and member of the Michael J. Fox Foundation Executive Scientific Advisory Board (2014-2016). Dr Isacson received The Lindahl Investigator Award from The Royal Swedish Academy of Sciences and the Bernard Sanberg Memorial Prize for Brain Repair. Prof. Isacson was President of the International Cell Transplant Society (TTS), (2007-2008), and served as a US government FDA member at the FDA Center for Biologics Evaluation and Research (CBER) (2014-2016); and the CSO of Pfizer’s Neuroscience Division (2016-2017). Prof. Isacson is the author or co-author of ~ 400 scientific research articles and 3 books in his field, and the Editor-in-Chief of Molecular and Cellular Neuroscience (2010-2016). Prof. Isacson was elected fellow of the American Association for the Advancement of Science (AAAS) in 2013.

Jonathan Keats

Lead Aitia Advisor for Multiple Myeloma, Lead MM Researcher at Tgen / City of Hope

Dr. Keats completed his PhD in Oncology at the University of Alberta and trained at the Mayo Clinic. His main research focus is on the genetics of multiple myeloma and other hematological diseases, and he leads a lab that concentrates on developing a better understanding of these diseases. His primary contributions to the field of multiple myeloma include characterization of the clinical impact of t(4;14), identification of constitutive activation of the NF-kB pathway, and defining the clonal evolution of myeloma tumors with time and therapeutic selection. Dr. Keats is the Director of Bioinformatics and an Assistant Professor in the Integrated Cancer Genomics Division at the Translational Genomics Research Institute in Phoenix, Arizona. He is also the Scientific Director of the Judy and Benard Briskin Center for
Multiple Myeloma Research at City of Hope.

William Kliitgard

Former President LabCorp’s Enlighten Health

Mr. William Klitgaard has over two decades of experience leading and advising healthcare businesses in the Healthcare IT and outsourced pharma services space. Mr. Klitgaard most recently served as President of Enlighten Health, a division of LabCorp (NYSE:LH) that focuses on innovation and creation of new information-based services utilizing core assets of LabCorp and Covance, Inc. Previously, he spent 19 years at Covance, one of the world’s largest contract research organizations, where he served for three years as Corporate Senior Vice President and Chief Information Officer, and nearly twelve years as Corporate Senior Vice President and Chief Financial Officer. Prior to his time at Covance, Mr. Klitgaard held finance leadership positions at Kenetech Corporation, a wind turbine manufacturer, and Consolidated Freightways, Inc., a freight service and logistics company.

Mr. Klitgaard earned a B.A. in economics from the University of California at Berkeley, and a Master’s degree from the Sloan Management School, Massachusetts Institute of Technology. He currently serves as a director of Certara, Inform Diagnostics, Syneos and XIFIN.

Peter Neupert

Lead Director at Adaptive and LabCorp, former Corporate Vice President at Microsoft and Founder/CEO of drugstore.com

As Corporate Vice President of the Microsoft Health Solutions Group, Peter was responsible for driving the company’s strategy to improve healthcare around the world through software innovation. He lead a global organization dedicated to developing, marketing, selling and supporting software solutions designed to improve the quality and efficiency of healthcare delivery and to empower individuals to become more engaged and responsible for their own health and wellness.

Under his leadership, the Health Solutions Group brought two primary software platforms to market: Amalga, a data aggregation platform for hospitals and health systems, and HealthVault, a personal health application platform designed to put individuals in control of their own health information. Both software platforms are designed to unlock the health data traditionally stored in separate information technology systems and make it readily accessible to the people who need it—whether emergency room doctors, primary care physicians, nurses, specialists, patients, or family caregivers—to make more informed care decisions.

Although Neupert began his career in technology, he became immersed in the world of health when he served as president and chief executive officer of drugstore.com Inc. from July 1998 to April 2001, and as chairman of the board of directors through September 2004. He led drugstore.com to become the leading online retail site for health, wellness, beauty and pharmacy products, and received an Ernst & Young Entrepreneur of the Year award for his work. From 2003 to 2005, he served on the President’s Information Technology Advisory Committee (PITAC), co-chairing the Health Information Technology subcommittee and helping to drive the “Revolutionizing Health Care through Information Technology” report, published in June 2004 by PITAC. Neupert was an active member of the Institute of Medicine’s Roundtable on Value & Science-Driven Healthcare from 2009 through 2011.

Neupert currently serves on the boards of Navigating Cancer and Truveta.

Neupert holds a master’s degree in business administration from the Tuck School of Business at Dartmouth College and a bachelor’s degree from Colorado College. He is married with four children and lives in the state of Washington.

Lee Newcomer

Board member of Myriad Genetics and CellWorks Former Senior Vice President, Oncology and Genetics, and Chief Medical Officer at UnitedHealth Group

Lee N. Newcomer, MD, MHA, is the former Senior Vice President, UnitedHealthcare with strategic responsibility for Oncology, Genetics and Women’s Health. Prior to rejoining United Health Group (UHG), Dr. Newcomer was a founding executive of Vivius, a consumer directed venture that allowed consumers to create their own personalized health plans. From 1991 to 2000, Dr. Newcomer held a number of positions at UHG, including Chief Medical Officer. His work there emphasized the development of performance measures and incentives to improve clinical care. Prior to joining UHG, he was Medical Director for CIGNA Health Care of Kansas City.

Dr. Newcomer is a board certified medical oncologist; he practiced medical oncology for nine years in Tulsa, Oklahoma and Minneapolis (Park Nicollet Clinic). He is the former Chairman of Park Nicollet Health Services, an integrated system of over 700 physicians and a 400 bed hospital. The group is nationally recognized for its leadership in quality, safety and lean processes. Dr. Newcomer earned a Bachelor of Arts degree in biology from Nebraska Wesleyan University, an MD degree from the University of Nebraska, College of Medicine, and an MS degree in health administration from the University of Wisconsin at Madison. He completed his internship and residency in internal medicine from the University of Nebraska Hospital, and fellowships in medical oncology and administrative medicine from the Yale University School of Medicine and the University of Wisconsin at Madison, respectively.

Under Dr. Newcomer’s leadership, UnitedHealthcare launched a program to test a bundled payment model for oncologists. His work in this area has been published in numerous leading oncology journals and presented at international conferences.

Ravi B. Parikh, MD, MPP, FACP

Aitia Chief Oncology Advisor Oncologist and Faculty Member at University of Pennsylvania & Board of Directors at Coalition to Transform Advanced Care

Ravi B. Parikh, MD, MPP, FACP, is an Assistant Professor in the Department of Medical Ethics and Health Policy and Medicine at the University of Pennsylvania and Staff Physician at the Corporal Michael J. Crescenz VA Medical Center. Dr. Parikh is a practicing medical oncologist with expertise in delivery system reform and informatics. His work has focused on three core areas: (1) the use of health technology to improve routine patient care; (2) quality of life and survivorship care in oncology; and (3) payment reform for advanced illnesses.

Dr. Parikh's work on medical technology and advanced illness in leading academic journals including Science, The New England Journal of Medicine, and JAMA. He is Senior Clinical Advisor and Board Member at the Coalition to Transform Advanced Care (C-TAC) and was elected to the National Council of Resident/Fellow Members of the American College of Physicians.

Dr. Parikh is a graduate of Harvard Medical School, Harvard College, and the John F. Kennedy School of Government. He completed a residency in internal medicine at Brigham and Women's Hospital and a fellowship in Hematology and Oncology at the University of Pennsylvania. He has received the National Palliative Care Research Center Kornfeld Scholars Award, Conquer Cancer Foundation Young Investigator Award, the American College of Physicians Joseph E. Johnson Leadership Award, and the AMA Foundation Excellence in Medicine Leadership Award.

Phil Rowlands, PhD

Independent Consultant, Oncology Drug Development Former head of Oncology R&D at Takeda Former VP, Asset Team Leader, Oncology Business Unit at Pfizer

Philip Rowlands, PhD is Head of the Oncology Therapeutic Area Unit (OTAU). In this role, he has overall responsibility for oncology R&D strategy, development portfolio goals and budget. The TAU consists of clinical, program leadership, and program and portfolio management functions, and has matrix leadership responsibility for all development programs from candidate selection through lifecycle management, via cross-functional program teams. Phil has spent his entire working career in the pharmaceuticals business starting in 1988 in developmental toxicology roles first at Zeneca/ICI and then at Sterling Drug in the UK. Through a series of roles of increasing responsibility in preclinical development, based in the UK, Europe, and then the US, he worked at Sterling, Sanofi, GD Searle and Pharmacia. In 2003, he transferred to Pfizer as an exploratory development director and has been focused exclusively on oncology drug development from that time. He spent eight years at Pfizer leading programs spanning early and late development, before moving to Takeda/Millennium in 2011.

Phil pursued his undergraduate training in pharmacology and toxicology in the UK, and went on to complete his doctoral thesis in mammalian embryology at the University of Leicester Medical School under Professor Felix Beck. He has been resident in the US since 1996 and is based with Takeda in Cambridge, Massachusetts.

Leadership

Colin Hill

Chief Executive Officer and Co-Founder

Bruce Church, PhD

Chief Mathematics Officer and EVP, Research and Early Development

Joseph F. Donahue

Chief Business Officer

Alan Kilyk

Chief Financial Officer

Jeanne Latourelle, D.Sc.

Senior Vice President Precision Medicine

Jerome Windsor, PharmD

Senior Vice President Business Development & Strategic Alliances

Board of Directors

John Maraganore, PhD

Chair of Aitia Board of Directors, Venture Partner at ARCH Venture Partners, Venture Advisor at Atlas Ventures, Executive Partner at RTW Investments. Former founding CEO and Director of Alnylam.

Colin Hill

Chief Executive Officer and Co-Founder

Jan Berger, MD, MJ

President & Chief Executive Officer, Health Intelligence Partners, Vice Chair of Aitia Board of Directors

Craig Cimini

Vice President of Strategy and Business Development & Cigna Ventures, Cigna

Rob Coppedge

President and Chief Executive Officer, Echo Health Ventures

Timothy Thompson

Independent Director & Former Chairman and Chief Executive Officer, Aptus Health

Adrian Weller, PhD

Senior Research Fellow, University of Cambridge Programme Director, Artificial Intelligence, The Alan Turing Institute

Board Observers

Joel Krikston

Managing Director Venture Investments/Head of Strategic Innovation Alliances, Merck Global Health Innovation Fund

David W. Miller, PhD

Operating Partner, GHO Capital

Samantha Palmer, PhD

Managing Director, Amgen Ventures

Advisors

Tom Daniel

Venture Partner at ARCH, former President of R&D at Celgene

Jean-Michel Gries

President of Hengenix Biotech and Head of Research for Henlius Biotech

Ole Isacson, PhD

Professor Neurology and Neuroscience Harvard Medical School, Massachusetts General Hospital, McLean Hospital, HSCI

Jonathan Keats

Lead Aitia Advisor for Multiple Myeloma, Lead MM Researcher at TGen / City of Hope

William Klitgaard

Former President LabCorp’s Enlighten Health

Peter Neupert

Lead Director at Adaptive and LabCorp, former Corporate Vice President at Microsoft and Founder and Chief Executive Officer of drugstore.com

Lee Newcomer

Board member of Myriad Genetics and CellWorksFormer Senior Vice President, Oncology and Genetics, and Chief Medical Officer at UnitedHealth Group

Ravi B. Parikh, MD, MPP, FACP

Aitia Chief Oncology AdvisorOncologist and Faculty Member at University of Pennsylvania & Board of Directors at Coalition to Transform Advanced Care

Phil Rowlands, PhD

Independent Consultant, Oncology Drug DevelopmentFormer head of Oncology R&D at TakedaFormer VP, Asset Team Leader, Oncology Business Unit at Pfizer

Our Investors

Colin Hill, MS

CEO and Co-Founder

Bruce Church, PhD

Chief Mathematics Officer and EVP, Research and Early Development

Joseph F. Donahue

Chief Business Officer

Alan Kilyk

CFO

Jeanne Latourelle, D.Sc.

Senior Vice President Precision Medicine

Jerome Windsor, PharmD

Senior Vice President Business Development & Strategic Alliances

John Maraganore, PhD

Aitia Chair of the Board of Directors, Venture Partner at ARCH Venture Partners, Venture Advisor at Atlas Ventures, Executive Partner at RTW Investments. Former founding CEO and Director of Alnylam.

Jan Berger, MD, MJ

President & Chief Executive Officer,Health Intelligence Partners

Vice Chair of Aitia Board of Directors

Craig Cimini

Vice President of Strategy and Business Development & Cigna Ventures, Cigna

Board Member

Rob Coppedge

Chief Executive Officer, Echo Health Ventures

Board Member

Timothy Thompson

Independent Director, Former Chairman and Chief Executive Officer, Aptus Health

Board member of Myriad Genetics and CellWorks
Former Senior Vice President, Oncology and Genetics, and Chief Medical Officer at UnitedHealth Group

Aitia Chief Oncology Advisor
Oncologist and Faculty Member at University of Pennsylvania & Board of Directors at Coalition to Transform Advanced Care

Independent Consultant, Oncology Drug Development
Former head of Oncology R&D at Takeda
Former VP, Asset Team Leader, Oncology Business Unit at Pfizer